Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Citius Oncology Ships First International Order of LYMPHIR™ to Europe PR Newswire - Wed Apr 29, 7:00AM CDT

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules PR Newswire - Fri Apr 24, 3:30PM CDT

CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7000 (+0.57%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules PR Newswire - Fri Apr 24, 7:00AM CDT

CRANFORD, N.J. , April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7000 (+0.57%)
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development PR Newswire - Tue Mar 31, 8:11AM CDT

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire - Tue Mar 24, 7:00AM CDT

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers PR Newswire - Tue Mar 10, 7:47AM CDT

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program PR Newswire - Tue Feb 24, 7:00AM CST

Non-dilutive capital supports continued execution and value creation

CTXR : 0.7000 (+0.57%)
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire - Fri Feb 13, 7:00AM CST

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PR Newswire - Wed Feb 11, 7:00AM CST

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire - Tue Dec 23, 2025

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

CTXR : 0.7000 (+0.57%)
CTOR : 0.9449 (+7.39%)

Barchart Exclusives

McDonald’s Is Down 4% and Starbucks Is Up 25% in 2026. The Better Dividend Stock Might Surprise You. Barchart - Fri May 1, 6:00PM CDT
Starbucks is up 25% in 2026 while McDonald's slipped 4%. So why might McDonald's still be the smarter dividend buy? The numbers tell a story most investors are missing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.